Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease

Pürner, Dominik; Hormozi, Mohammad; Weiß, Daniel; Barbe, Michael T.; Jergas, Hannah; Prell, Tino; Gülke, Eileen; Pötter-Nerger, Monika; Falkenburger, Björn; Klingelhöfer, Lisa; Gutsmiedl, Pia K.; Haslinger, Bernhard; Jochim, Angela M.; Wolff, Andreas; Schröter, Nils; Rijntjes, Michel; van Riesen, Christoph; Scheller, Ute; Wolz, Martin; Amouzandeh, Ali; Ebersbach, Georg; Gruber, Doreen; Kohl, Zacharias; Maetzler, Walter; Paschen, Steffen; Pérez-González, Pablo; Rozanski, Verena; Schwarz, Johannes; Südmeyer, Martin; Torka, Elisabeth; Wesbuer, Simone; Bornmann, Sarah; Flöel, Agnes; Ip, Chi Wang; Krause, Patricia; Kühn, Andrea A.; Csoti, Ilona; Herting, Birgit; van de Loo, Simone; Basheer, Aniz Ahammed; Liszka, Robert; Jost, Wolfgang H.; Koschel, Jiri; Haller, Bernhard; Lingor, Paul

doi:10.1212/wnl.0000000000207858

Cited by 1 publication

(2 citation statements)

References 44 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is also supported by several recent studies, which have shown that patients also benefit from a combination or sequential application of various intensified therapies. Several retrospective case series show that both the combination and the sequential use of intensified therapeutic procedures can lead to significant clinical improvement (Sesar et al 2019;Georgiev et al 2022;Pürner et al 2023). This is supported by a small prospective case series that showed a significant decrease in motor impairment with the addition of LCIG in patients with DBS and therapy-refractory symptoms (Regidor et al 2017).…”

Section: Deep Brain Stimulation (Dbs)mentioning

confidence: 89%

See 1 more Smart Citation

Advanced therapies in Parkinson’s disease: an individualized approach to their indication

Schröter,

Sajonz,

Jost

et al. 2024

J Neural Transm

Self Cite

View full text Add to dashboard Cite

Device aided therapies (DAT) comprising the intrajejunal administration of levodopa/carbidopa intestinal gel (LCIG) and levodopa/carbidopa/entacapone intestinal gel (LECIG), the continuous subcutaneous application of foslevodopa/foscarbidopa or apomorphine infusion (CSAI) and deep brain stimulation (DBS) are used to treat Parkinson’s disease with insufficient symptom alleviation under intensified pharmacotherapy. These DAT significantly differ in their efficacy profiles, indication, invasiveness, contraindications, and potential side effects. Usually, the evaluation of all these procedures is conducted simultaneously at the same point in time. However, as disease progression and symptom burden is extremely heterogeneous, clinical experience shows that patients reach the individual milestones for a certain therapy at different points in their disease course. Therefore, advocating for an individualized therapy evaluation for each DAT, requiring an ongoing evaluation. This necessitates that, during each consultation, the current symptomatology should be analyzed, and the potential suitability for a DAT be assessed. This work represents a critical interdisciplinary appraisal of these therapies in terms of their individual profiles and compares these DAT regarding contraindications, periprocedural considerations as well as their efficacy regarding motor- and non-motor deficits, supporting a personalized approach.

show abstract

Section: Deep Brain Stimulation (Dbs)mentioning

confidence: 89%

“…Depending on the clinical scenario, a patient may undergo multiple procedures consecutively, such as apomorphine as a bridging therapy for later DBS or pump therapy. It is also possible to combine therapies (Pürner et al 2023). To assist in the decisionmaking process, an international guideline was published in 2022 (Deuschl et al 2022).…”

Section: Introductionmentioning

confidence: 99%